Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

WGS vs TWST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TWST Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

TWST Overall Winner 6-Pillar Tally: WGS 3 – 3 TWST Matrix Metrics: WGS 5 – 5 TWST

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over GeneDx Holdings Corp. (WGS) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). WGS carries a Unified Composite Score of 49.5/100 (HOLD) at $51.02 (40.6x Forward P/E, -13.7% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin).

  • Technical & Structure Timing Caution: WGS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WGS vs TWST
WGS NASDAQ
GeneDx Holdings Corp. Class A Common Stock
Services-Health Services
$51.02
-2.58% 1D
Market Cap $1.6B
TTM Revenue $461M
Forward P/E 40.6x
Beta / 30D Vol 1.74β · 111% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.3%), weak momentum, RSI 35
RSI-14: 34.8 · SMA20: $62.47 · SMA50: $73.13
TWST NASDAQ Head-to-Head Winner
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.04
-5.88% 1D
Market Cap $7.4B
TTM Revenue $459M
Forward P/E N/M
Beta / 30D Vol 3.13β · 126% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.8 · SMA20: $137.31 · SMA50: $149.83

6-Pillar Scorecard Institutional Category Breakdown (WGS 3 – 3 TWST)

Columns: Metric · WGS · TWST
1. Valuation Multiples WGS
Forward P/E 40.6x N/M
Trailing P/E 38.8x N/M
PEG Ratio N/M N/M
EV / Revenue 3.7x 16.1x
2. Growth & Scale TWST
Revenue Growth (YoY) +5.4% +27.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $461M $459M
Market Cap $1.6B $7.4B
3. Profitability & Quality WGS
Gross Margin 68.8% 52.4%
Operating Margin -13.7% -28.8%
Net Profit Margin -24.1% -28.3%
Return on Equity (ROE) -41.4% -19.1%
4. Balance Sheet & Cash Flow WGS
Cash Generation (TTM) -$101M -$107M EBITDA
Cash Flow Margin -22.0% -23.4% EBITDA Mgn
Net Cash / Leverage $119M Net Debt (0.88x D/E) $13.61 Book/Sh · -19.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TWST
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 102.3% (21st %ile) 100.1% (19th %ile)
Put/Call OI Skew 7.82x (Put-Skewed) 1.04x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity 82.5% of Rev ($380M) 81.2% of Rev ($373M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WGS (5) vs TWST (5)
Institutional Metric WGS TWST Criterion Row Edge
Market Capitalization
Scale
$1.6B $7.4B Larger Scale TWST
Trailing P/E Ratio
Valuation
38.8x N/M Lower Multiple WGS
Forward P/E Ratio
Valuation
40.6x N/M Lower Multiple WGS
Revenue Growth (YoY)
Growth
+5.4% +27.9% Higher Growth TWST
Operating Margin (TTM)
Profitability
-13.7% -28.8% Higher Margin WGS
Net Profit Margin
Profitability
-24.1% -28.3% Higher Margin WGS
Return on Equity (ROE)
Capital Efficiency
-41.4% -19.1% Higher ROE TWST
52-Week Range Position
Momentum
14% ($32–$171) 42% ($23–$220) Stronger Trend TWST
Beta / 30D Volatility
Risk Regime
1.74β · 111% Vol 3.13β · 126% Vol Lower Realized Risk WGS
Unified Institutional Score
Composite Signal
49.5 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite TWST
Trailing 12M Revenue (USD)
Operating Scale
$461M $459M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.8% 52.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.7x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$101M ($119M Net Debt (0.88x D/E)) -$107M EBITDA ($13.61 Book/Sh · -19.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon WGS +1.08 pp
WGS: -19.79% · TWST: -20.87%
3M Horizon TWST +23.64 pp
WGS: -33.17% · TWST: -9.53%
6M Horizon TWST +91.46 pp
WGS: +19.51% · TWST: +110.97%
1Y Horizon TWST +312.16 pp
WGS: -60.86% · TWST: +251.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period WGS Revenue TWST Revenue WGS Op. Margin TWST Op. Margin Margin Leader
FY2018 N/A $30M N/A -277.5% TWST
FY2019 $200M $50M -15.5% -200.1% WGS
FY2020 $180M $90M -134.9% -155.5% WGS
FY2021 $210M $130M -210.3% -115.4% TWST
FY2022 $230M $200M -284.5% -115.3% TWST
FY2023 $200M $250M -89.2% -88.6% TWST
FY2024 $310M $310M -7.6% -70.6% WGS
FY2025 $430M $380M -3.1% -36.2% WGS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WGS BREAKDOWN
96d in phase · OBV DISTRIBUTION
Current IV 102.3%
IV Percentile 21st %ile
Put/Call OI Skew 7.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact WGS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 100.1%
IV Percentile 19th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WGS Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.6B market capitalization and -13.7% operating margin.
OpEx & R&D Reinvestment 82.5% of Rev ($380M)
90D Engineering Disclosures 0 Published
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.4B market capitalization and -28.8% operating margin.
OpEx & R&D Reinvestment 81.2% of Rev ($373M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ WGS vs TWST Key Questions & Quantitative Answers

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over GeneDx Holdings Corp. (WGS) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). WGS carries a Unified Composite Score of 49.5/100 (HOLD) at $51.02 (40.6x Forward P/E, -13.7% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin). Technical & Structure Timing Caution: WGS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TWST leads the Growth & Scale pillar: WGS posts +5.4% YoY revenue growth and +0.0% YoY earnings growth on $461M TTM revenue (68.8% gross margin, -13.7% operating margin), compared with TWST at +27.9% YoY revenue growth and +0.0% YoY earnings growth on $459M TTM revenue (52.4% gross margin, -28.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), WGS cumulative revenue shifted +115.0% while TWST shifted +1166.7%. In operating R&D and SG&A reinvestment, WGS deploys 82.5% of Rev ($380M) (0 90-day corporate R&D disclosures) versus 81.2% of Rev ($373M) (0 disclosures) for TWST.

WGS screens cheaper on headline valuation multiples. WGS trades at 40.6x Forward P/E, 38.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-22.0% FCF margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.1x EV/Revenue (-23.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WGS (-41.4% ROE) versus TWST (-19.1% ROE) capital efficiency.

In options market volatility and institutional positioning, WGS carries 102.3% implied volatility (21st %ile, Compressed (<25th %ile)), a 7.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 111% Vol realized risk). By comparison, TWST carries 100.1% implied volatility (19th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.